{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:25Z","timestamp":1788957385328,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.msard.2020.102725","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T22:00:30Z","timestamp":1609279230000},"page":"102725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["COVID-19 in ocrelizumab-treated people with multiple sclerosis"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5532-406X","authenticated-orcid":false,"given":"Richard","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-9853","authenticated-orcid":false,"given":"Louise","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kocho","family":"Fitovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-2336","authenticated-orcid":false,"given":"Hans-Martin","family":"Schneble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-0481","authenticated-orcid":false,"given":"Erwan","family":"Muros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licinio","family":"Craveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-6419","authenticated-orcid":false,"given":"Ulrike","family":"Bonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-0886","authenticated-orcid":false,"given":"Nikki","family":"Jessop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosetta","family":"Pedotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Koendgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102725_bib0001","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.25770","article-title":"SARS-CoV-2 and multiple sclerosis: not all immune-depleting DMTs are equal or bad","volume":"87","author":"Amor","year":"2020","journal-title":"Ann Neurol;"},{"issue":"2","key":"10.1016\/j.msard.2020.102725_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin Exp Immunol;"},{"key":"10.1016\/j.msard.2020.102725_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0004","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology;"},{"key":"10.1016\/j.msard.2020.102725_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","volume":"94","author":"Brownlee","year":"2020","journal-title":"Neurology;"},{"key":"10.1016\/j.msard.2020.102725_bib0006","unstructured":"Centers for Disease Control and Prevention (CDC). 2020a. Assessing risk factors for severe COVID-19 illness. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/assessing-risk-factors.html [accessed September 10, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0007","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.immunol.25.022106.141706","article-title":"The immunobiology of SARS","volume":"25","author":"Chen","year":"2007","journal-title":"Annu Rev Immunol;"},{"key":"10.1016\/j.msard.2020.102725_bib0008","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","article-title":"Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study","volume":"8","author":"Clark","year":"2020","journal-title":"Lancet Glob Health;"},{"key":"10.1016\/j.msard.2020.102725_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102315","article-title":"Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia","volume":"44","author":"Conte","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0010","doi-asserted-by":"crossref","DOI":"10.4046\/trd.2020.0095","article-title":"Risk factors for mortality among hospitalized patients with COVID-19. An overview in Mexican population","author":"Cort\u00e9s-Tell\u00e9s","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.msard.2020.102725_bib0011","unstructured":"COViMS Registry. 2020. The COViMS Database Public Data Update. Available at: www.COViMS.org. [accessed October 15, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"Cox","year":"2020","journal-title":"Nat Rev Immunol;"},{"key":"10.1016\/j.msard.2020.102725_bib0013","doi-asserted-by":"crossref","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","article-title":"Validation of an algorithm for identifying MS cases in administrative health claims datasets","volume":"92","author":"Culpepper","year":"2019","journal-title":"Neurology;"},{"key":"10.1016\/j.msard.2020.102725_bib0014","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/lt.25756","article-title":"Coronaviruses and immunosuppressed patients: the facts during the third epidemic","volume":"26","author":"D'Antiga","year":"2020","journal-title":"Liver Transpl;"},{"key":"10.1016\/j.msard.2020.102725_bib0015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2217\/imt-2020-0220","article-title":"Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins","volume":"12","author":"D\u00edez","year":"2020","journal-title":"Immunotherapy;"},{"key":"10.1016\/j.msard.2020.102725_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102334","article-title":"Factors associated with prescribing oral disease modifying agents in multiple sclerosis: a real-world analysis of electronic medical records","volume":"45","author":"Earla","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0017","unstructured":"European Centre for Disease Prevention and Control 2020. Available at: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/surveillance\/case-definition. [accessed October 8, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0018","unstructured":"European Medicines Agency, 1995. ICH Harmonised Tripartite Guideline E2A. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf [accessed October 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0019","article-title":"COVID-19 in immunocompromised hosts: what we know so far","author":"Fung","year":"2020","journal-title":"Clin"},{"key":"10.1016\/j.msard.2020.102725_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102135","article-title":"Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19","volume":"41","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102222","article-title":"Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic","volume":"43","author":"Ghajarzadeh","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0023","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s10072-020-04570-8","article-title":"Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?","volume":"41","author":"Ghajarzadeh","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.msard.2020.102725_bib0024","first-page":"188","article-title":"Charlson Comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.msard.2020.102725_bib0025","article-title":"Immunopathology of hyperinflammation in COVID-19","author":"Gustine","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.msard.2020.102725_bib0026","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/TCRM.S257714","article-title":"Managing disease-modifying therapies and breakthrough activity in multiple sclerosis patients during the COVID-19 pandemic: toward an optimized approach","volume":"16","author":"Hamdy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.msard.2020.102725_bib0027","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2020.102725_bib0028","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis. OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology;"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2020.102725_bib0029","first-page":"331","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis inpatients with relapsing and primary progressive multiple sclerosis","volume":"27","author":"Hauser","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.msard.2020.102725_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102192","article-title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab. A pharmacovigilance case series","volume":"42","author":"Hughes","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102725_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102442","article-title":"Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab","volume":"45","author":"Iannetta","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102725_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2020.109890","article-title":"Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters","volume":"188","author":"Ioannidis","year":"2020","journal-title":"Environ Res"},{"key":"10.1016\/j.msard.2020.102725_bib0033","unstructured":"ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium) COVID-19 Report: 4 October 2020. Available at: https:\/\/isaric.tghn.org [accessed October 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0034","unstructured":"Johns Hopkins, Coronavirus Resource Center. Mortality analyses. Available at: https:\/\/coronavirus.jhu.edu\/data\/mortality [accessed November 11, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0035","first-page":"2020","article-title":"COVID-19 and multiple sclerosis \u2013 prevalence and impact of disease-modifying therapies","author":"Kieseier","year":"2020","journal-title":"Presentation LB1252 given at the 8th Joint ACTRIMS-ECTRIMS Meeting"},{"key":"10.1016\/j.msard.2020.102725_bib0036","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.0000000000010378","article-title":"Vaccination in B-cell-depleted patients with multiple sclerosis","volume":"95","author":"Killestein","year":"2020","journal-title":"Neurology;"},{"key":"10.1016\/j.msard.2020.102725_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-020-0385-8","article-title":"Author correction: Neurological immunotherapy in the era of COVID-19 \u2013 looking for consensus in the literature","author":"Korsukewitz","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2020.102725_bib0038","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/1352458520942198","article-title":"COVID-19 in multiple sclerosis: the Dutch experience","volume":"26","author":"Loonstra","year":"2020","journal-title":"Mult Scler;"},{"key":"10.1016\/j.msard.2020.102725_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol;"},{"key":"10.1016\/j.msard.2020.102725_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102323","article-title":"Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report","volume":"44","author":"Lucchini","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102306","article-title":"COVID-19 in 7 multiple sclerosis patients in treatment with anti-CD20 therapies","volume":"44","author":"Meca-Lallana","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0042","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet;"},{"key":"10.1016\/j.msard.2020.102725_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102185","article-title":"Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain","volume":"42","author":"Montero-Escribano","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0044","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2020.102725_bib0045","unstructured":"U.S. Department of Health and Human Services NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf [accessed October 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","volume":"42","author":"Novi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102725_bib0047","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2020.102725_bib0048","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458520941485","article-title":"COVID-19 in people with multiple sclerosis: a global data sharing initiative","volume":"26","author":"Peeters","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2020.102725_bib0049","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2020.102725_bib0050","doi-asserted-by":"crossref","unstructured":"Rizzo S et\u00a0al. 2020. Descriptive epidemiology of 16,780 hospitalized COVID-19 patients in the United States. doi: 10.1101\/2020.07.17.20156265. [accessed October 14, 2020].","DOI":"10.1101\/2020.07.17.20156265"},{"key":"10.1016\/j.msard.2020.102725_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102725_bib0053","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS- CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.msard.2020.102725_bib0054","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy and Immunol;"},{"key":"10.1016\/j.msard.2020.102725_bib0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant;"},{"key":"10.1016\/j.msard.2020.102725_bib0056","unstructured":"Simpson-Yap S et\u00a0al. 2020. SS02.04 - First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes. Available at: https:\/\/cslide.ctimeetingtech.com\/msdc2020\/attendee\/confcal\/session\/calendar\/2020-09-26 session SS02-COVID-19. [accessed November 20, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0057","doi-asserted-by":"crossref","unstructured":"Sormani MP et\u00a0al. 2020. Disease modifying therapies and COVID-19 severity in multiple sclerosis. Available at: http:\/\/dx.doi.org\/10.2139\/ssrn.3631244 [accessed September 11, 2020].","DOI":"10.2139\/ssrn.3631244"},{"key":"10.1016\/j.msard.2020.102725_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102201","article-title":"Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab","volume":"42","author":"Suwanwongse","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0059","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol;"},{"key":"10.1016\/j.msard.2020.102725_bib0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7224\/1537-2073.2020-037","article-title":"Disease-modifying therapies during the COVID-19 outbreak: a narrative review of international and national recommendations","volume":"22","author":"Thakolwiboon","year":"2020","journal-title":"Int J MS Care;"},{"key":"10.1016\/j.msard.2020.102725_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102341","article-title":"Negative SARS-CoV-2 antibody testing following COVID-19 infection in two MS patients treated with ocrelizumab","volume":"44","author":"Thornton","year":"2020","journal-title":"Mult Scler Relat Disord;"},{"key":"10.1016\/j.msard.2020.102725_bib0062","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity;"},{"key":"10.1016\/j.msard.2020.102725_bib0063","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.msard.2020.102725_bib0064","article-title":"Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients","author":"Woo","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.102725_bib0065","unstructured":"World Health Organization. 2020a. Coronavirus disease (COVID-19) Situation Report \u2013106. Available at: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200505covid-19-sitrep-106.pdf?sfvrsn=47090f63_2 [accessed May 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0066","unstructured":"World Health Organization. 2020b. Available at: covid19.who.int [accessed October 15, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0067","unstructured":"World Health Organization. 2020c. Clinical management of COVID-19: interim guidance. 27 May 2020. Available at: https:\/\/www.who.int\/publications\/i\/item\/clinical-management-of-covid-19 [accessed October 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0068","unstructured":"World Health Organization. 2020d. Available at: https:\/\/www.who.int\/publications\/i\/item\/covid-19-therapeutic-trial-synopsis [accessed October 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0069","unstructured":"World Health Organization. 2020e. Estimating mortality from COVID-19 Scientific brief 4 August 2020. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 [accessed October 14, 2020]."},{"key":"10.1016\/j.msard.2020.102725_bib0070","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA;"},{"key":"10.1016\/j.msard.2020.102725_bib0071","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamainternmed.2020.4616","article-title":"Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.msard.2020.102725_bib0072","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458520943791","article-title":"Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient","volume":"26","author":"Wurm","year":"2020","journal-title":"Mult Scler;"},{"key":"10.1016\/j.msard.2020.102725_bib0073","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-020-00756-y","article-title":"Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination","volume":"34","author":"Zheng","year":"2020","journal-title":"CNS Drugs;"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:46Z","timestamp":1761900946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820307999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":73,"alternative-id":["S2211034820307999"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102725","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102725"}}